Nov 30, 2022 / 02:15PM GMT
Jonathan Miller - Evercore ISI - Analyst
Good morning, everybody, and welcome to our chat with Eric from Molecular Templates. Thanks so much for joining us again for another year of this conference, Eric. I'd love to start with -- well, let's start with a little intro from you. I think you've got multiple programs in the clinic right now, a lot of irons in the fire and some interesting initial clinical activity. So how do you view Molecular Templates going forward into the next year?
Questions and Answers:
Eric Poma - Molecular Templates, Inc. - CEO & Chief Scientific OfficerYeah. First, thanks again for the invite. This is always the best conference of the year, so my appreciations.
Jonathan Miller - Evercore ISI - Analyst
Say that to all the sell-siders, I'm sure.
Eric Poma - Molecular Templates, Inc. - CEO & Chief Scientific Officer
Sure. Look, I think it's been a good year for us. I think we have three drugs in the clinic that are either through Phase 1